Cangrelor: Difference between revisions
Martin Nino (talk | contribs) No edit summary |
Martin Nino (talk | contribs) No edit summary |
||
Line 4: | Line 4: | ||
|aOrAn=a | |aOrAn=a | ||
|drugClass=[[P2Y12 platelet inhibitor]] | |drugClass=[[P2Y12 platelet inhibitor]] | ||
|indicationType | |indicationType=indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk | ||
|indication= reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. | |||
}} | }} |
Revision as of 17:36, 17 January 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Martin Nino [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Cangrelor is a P2Y12 platelet inhibitor that is FDA approved for the indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Cangrelor FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Cangrelor FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
There is limited information regarding Cangrelor Contraindications in the drug label.
Warnings
There is limited information regarding Cangrelor Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Cangrelor Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Cangrelor Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Cangrelor Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Cangrelor in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cangrelor in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Cangrelor during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Cangrelor in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Cangrelor in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Cangrelor in geriatric settings.
Gender
There is no FDA guidance on the use of Cangrelor with respect to specific gender populations.
Race
There is no FDA guidance on the use of Cangrelor with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Cangrelor in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Cangrelor in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Cangrelor in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Cangrelor in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Cangrelor Administration in the drug label.
Monitoring
There is limited information regarding Cangrelor Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Cangrelor and IV administrations.
Overdosage
There is limited information regarding Cangrelor overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Cangrelor Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Cangrelor Mechanism of Action in the drug label.
Structure
There is limited information regarding Cangrelor Structure in the drug label.
Pharmacodynamics
There is limited information regarding Cangrelor Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Cangrelor Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Cangrelor Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Cangrelor Clinical Studies in the drug label.
How Supplied
There is limited information regarding Cangrelor How Supplied in the drug label.
Storage
There is limited information regarding Cangrelor Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Cangrelor |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Cangrelor |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Cangrelor Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Cangrelor interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Cangrelor Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Cangrelor Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.